Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Accumulated Expenses (2016 - 2022)

Cumberland Pharmaceuticals' Accumulated Expenses history spans 12 years, with the latest figure at $17.6 million for Q4 2022.

  • On a quarterly basis, Accumulated Expenses rose 102.9% to $17.6 million in Q4 2022 year-over-year; TTM through Dec 2022 was $17.6 million, a 102.9% increase, with the full-year FY2022 number at $17.6 million, up 102.9% from a year prior.
  • Accumulated Expenses hit $17.6 million in Q4 2022 for Cumberland Pharmaceuticals, up from $8.7 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for CPIX hit a ceiling of $17.6 million in Q4 2022 and a floor of $8.7 million in Q4 2021.
  • Historically, Accumulated Expenses has averaged $13.1 million across 5 years, with a median of $11.3 million in 2020.
  • Biggest five-year swings in Accumulated Expenses: plummeted 33.67% in 2019 and later surged 102.9% in 2022.
  • Tracing CPIX's Accumulated Expenses over 5 years: stood at $16.7 million in 2018, then plummeted by 33.67% to $11.1 million in 2019, then grew by 1.53% to $11.3 million in 2020, then decreased by 22.98% to $8.7 million in 2021, then surged by 102.9% to $17.6 million in 2022.
  • Business Quant data shows Accumulated Expenses for CPIX at $17.6 million in Q4 2022, $8.7 million in Q4 2021, and $11.3 million in Q4 2020.